ruffrecords
Well-known member
Quote by Angus Dalgleish, professor of oncology at the University of London.
"I've no concerns about leaving the EU - in fact it will be a blessed relief for people in my field. Britain used to be one of the best places in the world to do clinical trials. But the EU CLinical Trials Directive of 2004 more or less killed off the trials industry, with onerous, over cautious new regulations which have stifled innovation. Thus, researchers are now barred from looking for exciting new uses for old drugs - I, for example, conducted trials with with a TB vaccine in cancer patients - practices that used to yield breakthroughs. As for the allocation of grant money, this - as my experience on an EU cancer commission taught me - is mainly "determined by lobbying, not by peer reviewed decisions". Leaving the EU will allow us to escape this "constipated culture" and return to a "freer, researcher led and much more creative approach to regulating medical studies and saving lives"
Cheers
Ian
"I've no concerns about leaving the EU - in fact it will be a blessed relief for people in my field. Britain used to be one of the best places in the world to do clinical trials. But the EU CLinical Trials Directive of 2004 more or less killed off the trials industry, with onerous, over cautious new regulations which have stifled innovation. Thus, researchers are now barred from looking for exciting new uses for old drugs - I, for example, conducted trials with with a TB vaccine in cancer patients - practices that used to yield breakthroughs. As for the allocation of grant money, this - as my experience on an EU cancer commission taught me - is mainly "determined by lobbying, not by peer reviewed decisions". Leaving the EU will allow us to escape this "constipated culture" and return to a "freer, researcher led and much more creative approach to regulating medical studies and saving lives"
Cheers
Ian